To evaluate the current literature for tisagenlecleucel in the treatment of relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (ALL).
Data Sources
A literature search of PubMed (inception to June 18, 2020) and ClinicalTrials.gov was conducted using the following search terms: CTL019, chimeric antigen receptor, CAR-T, and tisagenlecleucel.
Study Selection and Data Extraction
All trials evaluating the use of tisagenlecleucel in B-cell ALL were reviewed and considered for inclusion.
Data Synthesis
Tisagenlecleucel displayed overall remission rates ranging from 69% to 93% in patients who historically respond extremely poorly to salvage therapy. Remissions were durable, with 12-month relapse-free survival (RFS) rates of 55% to 59%. These promising results are tempered by the unique adverse effect profile of chimeric antigen receptor (CAR) T-cell therapy. Potentially life-threatening cytokine release syndrome (CRS) occurred in 77% to 100% of patients, and immune effector cell–associated neurotoxicity syndrome (ICANS) developed in 31% to 45% of patients receiving tisagenlecleucel.
Relevance to Patient Care and Clinical Practice
The successful utilization of tisagenlecleucel therapy requires meticulous planning, prudent patient selection, multidisciplinary collaboration, and expert training to ensure optimal patient care. The complex interplay of patient- and treatment-related factors creates problematic barriers that must be expertly navigated by the health care team and authorized treatment center.
Conclusions
As the first US Food and Drug Administration–approved gene therapy, tisagenlecleucel heralds an immunotherapeutic breakthrough for treating pediatric and young adult patients with r/r B-cell ALL. Many questions surrounding patient-specific gene and cellular therapies remain, but their transformative potential in cancer care remains promising.
JabbourEJFederlSKantarjianHM.Adult acute lymphoblastic leukemia. Mayo Clin Proc. 2005;80:1517-1527. doi:10.4065/80.11.1517
2.
HucksGRheingoldSR.The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL. Blood Cancer J. 2019;9:10. doi:10.1038/s41408-018-0164-6
3.
VairySGarciaJLTeiraPBittencourtH. CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia. Drug Des Devel Ther. 2018;12:3885-3898. doi:10.2147/DDDT.S138765
4.
NguyenKDevidasMChengSC, et al; Children’s Oncology Group. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children’s Oncology Group study. Leukemia. 2008;22:2142-2150. doi:10.1038/leu.2008.251
5.
LocatelliFSchrappeMBernardoME, et al. How I treat relapsed childhood acute lymphoblastic leukemia. Blood. 2012;120:2807-2816. doi:10.1182/blood-2012-02-265884
6.
WardEDeSantisCRobbinsAKohlerAJemalA.Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64:83-103. doi:10.3322/caac.21219
7.
PulteDJansenLGondosA, et al; GEKID Cancer Survival Working Group. Survival of adults with acute lymphoblastic leukemia in Germany and the United States. PLoS One. 2014;9:e85554. doi:10.1371/journal.pone.0085554
8.
SiveJIBuckGFieldingA, et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. Br J Haematol. 2012;157:463-471. doi:10.1111/j.1365-2141.2012.09095.x
9.
TallenGRateiRMannG, et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol. 2010;28:2339-2347. doi:10.1200/JCO.2009.25.1983
10.
HahnTWallDCamittaB, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant. 2006;12:1-30. doi:10.1016/j.bbmt.2005.10.018
11.
EapenMRaetzEZhangMJ, et al; Children’s Oncology Group; Center for International Blood and Marrow Transplant Research. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children’s Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood. 2006;107:4961-4967. doi:10.1182/blood-2005-12-4942
12.
KantarjianHMDeAngeloDJStelljesM, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375:740-753. doi:10.1056/NEJMoa1509277
13.
von StackelbergALocatelliFZugmaierG, et al. Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol. 2016;34:4381-4389. doi:10.1200/JCO.2016.67.3301
14.
ToppMSGökbugetNSteinAS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicenter, single-arm, phase 2 study. Lancet Oncol. 2015;16:57-66. doi:10.1200/JCO.2016.67.3301. Published correction appears in Lancet Oncol. 2015;16:e158.
15.
JehaSHaynonPSRazzoukBI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol. 2006;24:1917-1923. doi:10.1200/JCO.2005.03.8554
16.
O’BrienSSchillerGListerJ, et al. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol. 2013;31:676-683. doi:10.1200/JCO.2012.46.2309
17.
BraendstrupPLevineBLRuellaM.The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19. Cytotherapy. 2020;22:57-69. doi:10.1016/j.jcyt.2019.12.004
MoherDLiberatiATetzlaffJAltmanDG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264-269, W64. doi:10.7326/0003-4819-151-4-200908180-00135
20.
EhrlichP.Ueber den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskd. 1909;5:273-290.
21.
LuBFinnOJ.T-cell death and cancer immune tolerance. Cell Death Differ. 2008;15:70-79. doi:10.1038/sj.cdd.4402274
22.
GalonJCostesASanchez-CaboF, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960-1964. doi:10.1126/science.1129139
23.
JuneCHMausMVPlesaG, et al. Engineered T cells for cancer therapy. Cancer Immunol Immunother. 2014;63:969-975. doi:10.1007/s00262-014-1568-1
24.
MuellerKTWaldronEGruppSA, et al. Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia. Clin Cancer Res. 2018;24:6175-6184. doi:10.1158/1078-0432.CCR-18-0758
25.
CerranoMRuellaMPeralesMA, et al. The advent of CAR T-cell therapy for lymphoproliferative neoplasms: integrating research into clinical practice. Front Immunol. 2020;11:888. doi:10.3389/fimmu.2020.00888
GeorgePDasyamNGiuntiG, et al. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE). BMJ Open. 2020;10:e034629. doi:10.1136/bmjopen-2019-034629
29.
ScheuermannRHRacilaE.CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma. 1995;18:385-397. doi:10.3109/10428199509059636
30.
WangKWeiGLiuD.CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012;1:36. doi:10.1186/2162-3619-1-36.
31.
MuellerKTMaudeSLPorterDL, et al. Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocyte leukemia. Blood. 2017;130:2317-2325. doi:10.1182/blood-2017-06-786129
32.
MaudeSLLaetschTWBuechnerJ, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439-448. doi:10.1056/NEJMoa1709866
33.
MaudeSLFreyNShawPA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507-1517. doi:10.1056/NEJMoa1407222
34.
MaudeSLTeacheyDTRheingoldSR, et al. Sustained remissions with CD-19 specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL. J Clin Oncol. 2016;34(suppl 15):3011. doi:10.1200/JCO.2016.34.15_suppl.3011
35.
MaudeSLPulsipherMABoyerMW, et al. Efficacy and safety of CTL019 in the first US phase II multicenter trial in pediatric relapsed/refractory acute lymphoblastic leukemia: results of an interim analysis. Blood. 2016;128:2801. doi:10.1182/blood.V128.22.2801.2801
36.
GruppSAMaudeSLRivesS, et al. Updated analysis of the efficacy and safety of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory (r/r) acute lymphoblastic leukemia. Blood. 2018;132(suppl 1):895. doi:10.1182/blood-2018-99-112599
37.
JuneCHSadelainM.Chimeric antigen receptor therapy. N Engl J Med. 2018;379:64-73. doi:10.1056/NEJMra1706169
38.
US Department of Health and Human Services, National Institutes of Health. Common Terminology Criteria for Adverse Events. Version 4.03. US Department of Health and Human Services; 2010.
39.
LeeDWGardnerRPorterDL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188-195. doi:10.1182/blood-2014-05-552729
40.
LeeDWSantomassoBDLockeFL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625-638. doi:10.1016/j.bbmt.2018.12.758
41.
BrudnoJNKochenderferJN.Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019;34:45-55. doi:10.1016/j.blre.2018.11.002
42.
FitzgeraldJCWeissSLMaudeSL, et al. Cytokine release syndrome after chimeric antigen receptor t cell therapy for acute lymphoblastic leukemia. Crit Care Med. 2017;45:e124-e131. doi:10.1097/CCM.0000000000002053
43.
NeelapuSSTummalaSKebriaeiP, et al. Chimeric antigen receptor T-cell therapy—assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47-62. doi:10.1038/nrclinonc.2017.148
44.
Actemra. Package insert. Genentech; 2017.
45.
MahadeoKMKhazalSJAbdel-AzimH, et al; Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat Rev Clin Oncol. 2019;16:45-63. doi:10.1038/s41571-018-0075-2
NeelapuSS.Managing the toxicities of CAR T-cell therapy. Hematol Oncol. 2019;37(suppl 1):48-52. doi:10.1002/hon.2595
49.
DavilaMLBrentjensRJ.CD19-targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2016;14:802-808.
50.
GustJHayKAHanafiLA, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7:1404-1449. doi:10.1158/2159-8290.CD-17-0698
51.
ChenFTeacheyDTPequignotE, et al. Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. J Immunol Methods. 2016;434:1-8. doi:10.1016/j.jim.2016.03.005
52.
MahmoudjafariZHawksKGHsiehAA, et al. American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group Survey on chimeric antigen receptor T cell therapy administrative, logistic, and toxicity management practices in the United States. Biol Blood Marrow Transplant. 2019;25:26-33. doi:10.1016/j.bbmt.2018.09.024
53.
NishimotoNTeraoKMimaTNakaharaHTakagiNKakehiT.Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112:3959-3964. doi:10.1182/blood-2008-05-155846
54.
HungerSPMullighanCG.Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373:1541-1552. doi:10.1056/NEJMra1400972
55.
NorelliMCamisaBBarbieraG, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24:739-748. doi:10.1038/s41591-018-0036-4
56.
GiavridisTvan der StegenSJCEyquemJHamiehMPiersigilliASadelainM.CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24:731-738. doi:10.1038/s41591-018-0041-7
57.
SternerRMSakemuraRCoxMJ, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019;133:697-709. doi:10.1182/blood-2018-10-881722
58.
GökbugetNStanzeDBeckJ, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120:2032-2041. doi:10.1182/blood-2011-12-399287
59.
MoussalemMEsperou BourdeauHDevergieA, et al. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission: factors predictive of survival, relapse and graft-versus-host disease. Bone Marrow Transplant. 1995;15:943-947.
60.
PrasadV.Immunotherapy: tisagenlecleuce—the first approved CAR-T-cell therapy: implications for payers and policy makers. Nat Rev Clin Oncol. 2018;15:11-12. doi:10.1038/nrclinonc.2017.156
61.
BroderMSQuockTPChangE, et al. The cost of hematopoietic stem-cell transplantation in the United States. Am Health Drug Benefits. 2017;10:366-374.
62.
ManzCRPorterDLBekelmanJE.Innovation and access at the mercy of payment policy: the future of chimeric antigen receptor therapies. J Clin Oncol. 2020;38:384-387. doi:10.1200/JCO.19.01691
63.
MariottoABYabroffKRShaoYFeuerEJBrownML.Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103:117-128. doi:10.1093/jnci/djq495
64.
SarkerRRGloudeNJSchiffDMurphyJD.Cost-effectiveness of chimeric antigen receptor t-cell therapy in pediatric relapsed/refractory b-cell acute lymphoblastic leukemia. J Natl Cancer Inst. 2019;111:719-726. doi:10.1093/jnci/djy193
YuXJHubbard-LuceyVMTangJ.The global pipeline of cell therapies for cancer. Nat Rev Drug Discov. 2019;18:821-822. doi:10.1038/d41573-019-00090-z.
67.
HwuPShaferGETreismanJ, et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. Exp Med. 1993;178:361-366. doi:10.1084/jem.178.1.361
68.
HwuPYangJCCowherdR, et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res. 1995;55:3369-3373.
KlebanoffCAKhongHTAntonyPAPalmerDCRestifoNP.Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 2005;26:111-117. doi:10.1016/j.it.2004.12.003
71.
ImaiCMiharaKAndreanskyM, et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia. 2004;18:676-684. doi:10.1038/sj.leu.2403302
72.
BrentjensRJSantosENikhaminY, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res. 2007;13(18, pt 1):5426-5435. doi:10.1158/1078-0432.CCR-07-0674
73.
DudleyMEWunderlichJRRobbinsPF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854. doi:10.1126/science.1076514
74.
ZhangHSnyderKMSuhoskiMM, et al. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. J Immunol. 2007;179:4910-4918. doi:10.4049/jimmunol.179.7.4910
75.
PorterDLLevineBLKalosMBaggAJune CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725-733. doi:10.1056/NEJMoa1103849
76.
GruppSAKalosMBarrettD, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509-1518. doi:10.1056/NEJMoa1215134
GofshteynJSShawPATeacheyDT, et al. Neurotoxicity after CTL019 in a pediatric and young adult cohort. Ann Neurol. 2018;84:537-546. doi:10.1002/ana.25315
